CAVD 232
CAVD 232 is an NHP challenge study comparing a CMV vaccine, RhCMV-SIV, to a control RhCMV vector, and a vaccine-naïve group.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Christopher Parks
Parks: Replicating Viral Vaccine Vectors

Vector vaccines (viral or bacterial)

SIVmac239
CMV-SIV
Placebo CMV
None

Inactive
Start: 2009-11-24
End: 2014-10-15

CAVD 234
CAVD 234 is a monoclonal antibody screening study to evaluate the neutralization activity of monoclonal antibodies isolated from rabbits.

No data is available for this study.

Antibody Screening
Non-Organism Study

Susan Zolla-Pazner
Zolla-Pazner: Epitope-Scaffold Immunogens

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2009-02-03
End: 2013-05-23

CAVD 235
CAVD 235 is a monoclonal antibody study to characterize mAbs isolated and produced from IgG+ memory B cells of non-clade B HIV-1 infected donors, using a representative panel of HIV-1 primary isolates.

No data is available for this study.

Antibody Screening
Non-Organism Study

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2008-08-21
End: 2012-06-15

CAVD 236
CAVD 236 is a monoclonal antibody screening study using monoclonal antibodies isolated from humans. No additional information available at this time.

No data is available for this study.

Antibody Screening
Non-Organism Study

Susan Zolla-Pazner
Zolla-Pazner: Epitope-Scaffold Immunogens

Prophylactic neutralizing Ab

No Products used in study

Active
Start: 2009-02-03
End:

CAVD 238
CAVD 238 is a monoclonal antibody screening study evaluating broadly neutralizing antibodies in chronically infected, long-term non-progressors, with the primary objective to examine the relationship between HIV-1 antigenic load (plasma RNA copies/mL) and broad HIV-1 neutralizing antibody activity.

No data is available for this study.

Antibody Screening
Non-Organism Study

Robert Gallo
Gallo: Systemic, Mucosal & Passive Immunity

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2009-01-08
End: 2015-05-06

CAVD 239
CAVD 239 (CAVIMC-015) is a non-human primate challenge study comparing 5 different peptide/protein/adjuvant regimens including HLA-antigens and/or HIV-1 gp120/SIVp27 antigens.

NAb

Pre-Clinical NHP
Rhesus macaque

Thomas Lehner
Lehner VDC

Protein & peptide vaccines

HIV-1 gp140
Titermax
SIV-Gag p27
HSP 70
MHC Class I and II
SHIV-SF162P4
None

Inactive
Start: 2009-01-08
End: 2012-03-28

CAVD 240
CAVD 240 is a non-human primate challenge study comparing the envelope-based subunit protein, rhFLSC, versus gp120, when combined with two different adjuvants (RC529, a TLR4 agonist; and Iscomatrix, a saponin-containing ISCOM.)

NAb

Pre-Clinical NHP
Rhesus macaque

Robert Gallo
Gallo: Systemic, Mucosal & Passive Immunity

Protein & peptide vaccines

rhFLSC Protein
SHIV162p3
RC529
Iscomatrix
GPI-0100
BaL gp120
rhesus CD4 D1D2
Tat

Inactive
Start: 2008-12-11
End: 2013-07-25

CAVD 242
CAVD 242 is a preclinical rabbit study comparing several recombinant clade C HIV gp140/adjuvant regimens in which the antigen was attached to microparticles in an effort to expose different epitopes.

NAb

Pre-Clinical Non-NHP
Rabbit

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Protein & peptide vaccines

Gel
MF59
ZM96 gp140
Wax particles
PLA particles

Inactive
Start: 2009-04-02
End: 2013-04-30

CAVD 244
CAVD 244 (ADVAX) is a Phase I clinical trial to evaluate the effect of two vaccinations with ADVAX (Clade C/B muligenic DNA-based vaccine) administered either via in vivo electroporation or standard intramuscular injection in 40 healthy HIV-negative volunteers.

No data is available for this study.

Phase I
Human

David Ho
NA

DNA vaccines

Saline (non-specific)
ADVAX

Active
Start: 2008-03-10
End:

CAVD 245
CAVD 245 evaluates how sequence changes in the MPER of gp41 affect MPER conformation and neutralization sensitivity by anti-MPER broadly neutralizing antibodies.

NAb MAb

Antibody Screening
Non-Organism Study

Ellis Reinherz
Reinherz: bNAbs Against Clade C

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2010-04-05
End: 2013-05-21

CAVD 247
CAVD 247 is a non-human primate study comparing 2nd generation live recombinant Bacillus Calmette Guérin (rBCG) with wildtype BCG in BCG/NYVAC prime/boost regimens. The animals immunized with the rBCG mutants showed enhanced immunogenicity in comparison to animals immunized with the parental rBCG Danish control.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Norman Letvin
Letvin: rAdenoviral & rMycobacterial Vector Immunogens

Vector vaccines (viral or bacterial)

BCG Dan WT
BCG Dan10
BCG Dan10 AF25
BCG J13R10
BCG J13R7
rNYVAC-SIV-Gag-Pol vp1042 (Mac142)
rDNA SIV-Gag-Pol-Nef

Inactive
Start: 2010-06-06
End: 2013-07-25

CAVD 256
CAVD 256 (EV03/ANRSVAC20) is Phase I/II study to compare the immunogenicity and safety of 3 DNA-C prime followed by 1 NYVAC-C boost to 2 DNA-C prime followed by 2 NYVAC-C boost.

BAMA, NAb

Phase I/II
Human

Giuseppe Pantaleo
Pantaleo: Poxvirus-Based Vaccine Development

Combo: DNA & vector vaccines

NYVAC-C (vP2010)
DNA-C

Inactive
Start: 2010-08-04
End: 2013-08-16

CAVD 258
CAVD 258 is a non-human primate study comparing prime/boost regimens using NYVAC-C-KC and NYVAC-C combined with DNA and protein vaccines.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Giuseppe Pantaleo
Pantaleo: Poxvirus-Based Vaccine Development

Combo: DNA, protein & vector vaccines

Product info coming soon!

Active
Start: 2010-11-15
End:

CAVD 259
CAVD 259 (AUP444/CAVIMC-033) is a non-human primate study comparing 5 different prime/boost regimens of NYVAC-C-KC or NYVAC-C in combination with DNA-C, protein, and MF59.

BAMA, ICS, ELISpot, NAb

Pre-Clinical NHP
Rhesus macaque

Giuseppe Pantaleo
Pantaleo: Poxvirus-Based Vaccine Development

Combo: DNA, protein & vector vaccines

NYVAC-C-KC
NYVAC-C (vP2010)
MF59
DNA-C
HIV-1 C Env

Inactive
Start: 2010-11-16
End: 2013-08-16

CAVD 260
CAVD 260 is a non-human primate challenge study comparing prime/boost regimens of a Modified Vaccinia Ankara vaccine combined with envelope protein vaccine and the adjuvant, Poly-ICLC .

NAb

Pre-Clinical NHP
Rhesus macaque

Julie McElrath
McElrath: Innate to Adaptive Immunity

Combo: Protein & vector vaccines

SIVmac251
Rapamycin
Placebo MVA
Poly IC
MVA-SIV-Env
SIV-Env

Inactive
Start: 2010-12-17
End: 2014-11-10

CAVD 261
CAVD 261 is an immunogenicity study to assess the potency and breadth of the humanized monoclonal antibody, Ibalizumab, against a diverse virus panel.

No data is available for this study.

Antibody Screening
Non-Organism Study

David Ho
Ho: Ibalizumab for HIV Prevention

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2010-12-21
End: 2016-02-16

CAVD 262
CAVD 262 is an immunogenicity study to characterize structural variants of neutralizing antibodies and their performance and expression levels in vivo.

No data is available for this study.

Antibody Screening
Non-Organism Study

James Wilson
Wilson: Vector-Mediated Passive Immunization

Prophylactic neutralizing Ab

Product info coming soon!

Inactive
Start: 2010-01-04
End: 2014-10-20

CAVD 263
CAVD 263 (CAVIMC-035/NYU-11) is a preclinical rabbit study comparing DNA/Protein prime/boost regimens using C1.opt DNA and varying subunit virus like particle (VLPs) proteins.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Susan Zolla-Pazner
Zolla-Pazner: Epitope-Scaffold Immunogens

Combo: DNA & VLP vaccines

DNA (gp120.C1-opt)
V3/B
V3/C
VLP - HPV - L1
VLP - PP7
CTB protein

Inactive
Start: 2011-02-01
End: 2012-06-11

CAVD 264
CAVD 264 (DC Vax/SSC-0710) is a clinical trial comparing increasing dose of the monoclonal antibody vaccine, DEC-205-p24.

BAMA, ICS

Phase I
Human

Sarah Schlesinger
Steinman: Dendritic Cells & Flavivirus Vectors

Prophylactic neutralizing Ab

DC-VAX
Hiltonol
Saline

Inactive
Start: 2011-02-15
End: 2015-10-19

CAVD 265
CAVD 265 is a study evaluating and comparing the functionality of 3 pairs of chemically modified vs. unmodified neutralizing monoclonal antibodies.

No data is available for this study.

Antibody Screening
Non-Organism Study

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2011-03-28
End: 2012-09-12

CAVD 266
CAVD 266 (VRC 284) is non-human primate study comparing several envelope protein and adjuvant regimens, to directly compare the effects of different adjuvants. A follow up study (CAVD 417) was performed.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Julie McElrath
McElrath: Innate to Adaptive Immunity

Protein & peptide vaccines

Alum
Iscomatrix
MF59
Poly ICLC
gp140 C
TLR4
TLR7

Inactive
Start: 2010-09-13
End: 2014-03-07

CAVD 267
CAVD 267 is a non-human primate study comparing boost regimens of increasing doses of NYVAC in subjects primed with BCG and Ad5 vaccines. This was a follow up boost study to CAVD 294.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Norman Letvin
Letvin: rAdenoviral & rMycobacterial Vector Immunogens

Vector vaccines (viral or bacterial)

rNYVAC-SIV-Gag
rAd5-SIV
rBCG Pasteur

Inactive
Start: 2011-04-07
End: 2013-05-21

CAVD 268
CAVD 268 evaluates immune responses in samples from the MUCOVAC2 Phase I clinical trial, which assessed CN54 gp140 immunization at different doses with different routes and adjuvants.

No data is available for this study.

Phase I
Human

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Protein & peptide vaccines

GLA-AF
Chitosan
CN54 gp140
Gel 2734

Inactive
Start: 2011-06-27
End: 2015-10-19

CAVD 269
CAVD 269 (NYU-12) is a preclinical rabbit study comparing immunization regimens with and without DNA priming using gp140-CN54 or (V3C-V3 + V33074-CTB) protein immunogens

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Susan Zolla-Pazner
Zolla-Pazner: Epitope-Scaffold Immunogens

Combo: DNA & protein vaccines

IFA
DNA (gp120.C1-opt)
V3/3074 CTB
V3/C
gp140 CN54

Inactive
Start: 2011-08-02
End: 2012-06-11

CAVD 270
CAVD 270 is an immunogenicity study of broadly neutralizing antibodies.

NAb MAb

Antibody Screening
Non-Organism Study

Dennis Burton
Third party request

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2011-08-15
End: 2013-07-25

CAVD 271
CAVD 271 is a guinea pig study evaluating whether fixation of gp140 can better preserve the trimeric conformation and elicit antibodies specific to neutralizing epitopes.

NAb

Pre-Clinical Non-NHP
Guinea Pig

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

gp140 UG37 WT
gp140 UG37 Fixed
Carbopol 971

Inactive
Start: 2011-08-20
End: 2016-03-14

CAVD 272
CAVD 272 is an immunogenicity study to evaluate the in vitro neutralization activity of Glyco iMab, a glycan-modified Ibalizumab variant.

No data is available for this study.

Antibody Screening
Non-Organism Study

David Ho
Ho: Ibalizumab for HIV Prevention

Prophylactic neutralizing Ab

Glyco iMab

Inactive
Start: 2011-08-31
End: 2013-02-08

CAVD 273
CAVD 273 is a guinea pig study assessing immune focusing response with gp140-CA018 and V3 were immunized in guinea pigs alone or in prime boost combination with different adjuvants.

No data is available for this study.

Pre-Clinical Non-NHP
Guinea Pig

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

MF59
Carbopol 971
Env gp140 CA018
V3 mimetic

Inactive
Start: 2011-11-03
End: 2012-08-09

CAVD 274
CAVD 274 is a guinea pig study that employs two different gp41 proteoliposome formulations that contain fusion intermediate conformations of gp41 fragments inserted or attached to liposomes.

No data is available for this study.

Pre-Clinical Non-NHP
Guinea Pig

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

Env gp140 CA018
V3 mimetic
gp41 liposome A
gp41 liposome B
Liposome A
Liposome B

Inactive
Start: 2011-11-03
End: 2012-09-12

CAVD 275
CAVD 275 is an immunogenicity study to assess the neutralization activity of antibody fragments (Fab fragments) and peptides against HIV.

NAb MAb

Antibody Screening
Non-Organism Study

David Ho
Ho: Ibalizumab for HIV Prevention

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2011-11-21
End: 2015-08-18

CAVD 276
CAVD 276 (CAVD 372) is a rabbit study comparing wild type with aldehyde cross-linked gp140 in carbopol adjuvant using a prime and two boosts protocol.

NAb

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

PEI
Carbopol 971
gp140 WT
Aldehyde cross-linked gp140

Inactive
Start: 2011-12-13
End: 2013-07-25

CAVD 277
CAVD 277 (AUP485/CAVIMC-040) is a non-human primate study comparing 3 different prime/boost regimens using DNA-C, NYVAC-C, and protein vaccines.

BAMA, ICS, ELISpot, NAb

Pre-Clinical NHP
Rhesus macaque

Giuseppe Pantaleo
Pantaleo: Poxvirus-Based Vaccine Development

Combo: DNA & vector vaccines

NYVAC-C (vP2010)
MF59
DNA-C
gp120 C.1086
gp120 TV1

Inactive
Start: 2011-12-14
End: 2013-08-13

CAVD 278
CAVD 278 (CAVIMC-040) is an immunogenicity study to define the epitopes recognized by a panel of anti-gp41 monoclonal antibodies that mediate ADCC.

No data is available for this study.

Antibody Screening
Non-Organism Study

George Lewis
Lewis: Ab Specificity & Fc-Mediated Protection

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-01-12
End: 2012-10-10

CAVD 279
CAVD 279 is an immunogenicity study of V2-specific monoclonal antibodies.

No data is available for this study.

Antibody Screening
Non-Organism Study

Shan Lu
Lu: Creating a Better Envelope

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2011-12-12
End: 2013-07-25

CAVD 281
CAVD 281 (AUP 513) is a non-human primate study comparing NYVAC/ALVAC prime/boost regimens.

BAMA, ICS, NAb

Pre-Clinical NHP
Rhesus macaque

Giuseppe Pantaleo
Pantaleo: Poxvirus-Based Vaccine Development

Combo: Protein & vector vaccines

NYVAC-C-KC-ΔB19R
ALVAC (vCP1521)
AIDSVAX B/E
Alum
MF59
NYVAC-C-Gag-Pol-Nef
NYVAC-C-gp140
gp120 C.1086
gp120 TV1
NYVAC-KC-gp140(ZM96)
NYVAC-KC-Gag(ZM96)Pol-Nef(CN54)
NYVAC-KC-deltaB19-Gag(ZM96)Pol-Nef(CN54)
ALVAC-Gag Pol Nef
ALVAC-gp140

Inactive
Start: 2012-01-25
End: 2016-11-10

CAVD 282
CAVD 282 (CAVIMC-043) is a guinea pig study assessing variants of Clade C ZM96 Env for their ability to induce binding antibodies.

No data is available for this study.

Pre-Clinical Non-NHP
Guinea Pig

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Combo: DNA & protein vaccines

ZM96 gp140
ZM96gp140 DNA
ZM96 gp140 A37
ZM96 gp140 A39
ZM96 gp140 A46
ZM96 gp140 A47
ZM96gp140 A37 DNA
ZM96gp140 A39 DNA
ZM96gp140 A46 DNA
ZM96gp140 A47 DNA
pCDNA 3.1

Inactive
Start: 2012-02-06
End: 2013-03-21

CAVD 283
CAVD 283 (CAVIMC-042) is a guinea pig study assessing variants of Env and variants of delivery methods for qualitative differences in nAb responses.

No data is available for this study.

Pre-Clinical Non-NHP
Guinea Pig

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

DNA vaccines

Product info coming soon!

Inactive
Start: 2012-02-06
End: 2013-03-21

CAVD 284
CAVD 284 is a preclinical rabbit study assessing neutralization activity induced by the clade C trimeric gp140 antigen derived from clade C HIV-1 CN54, combined with different adjuvants

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

Alum
PEI
CFA
IFA
CpG DNA
ZM96 gp140

Inactive
Start: 2007-03-26
End: 2011-06-21

CAVD 285
CAVD 285 is a continuation of CAVD 284, assessing the neutralization activity induced by the clade C trimeric gp140 antigen derived from clade C HIV-1 CN54, combined with different adjuvants.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

Alum
PEI
CFA
IFA
CpG DNA
ZM96 gp140

Inactive
Start: 2007-05-22
End: 2011-06-21

CAVD 286
CAVD 286 is an immunogenicity study of samples from a preclinical rabbit study of a recombinant Clade C protein.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Protein & peptide vaccines

ZM96 gp140-651.8

Inactive
Start: 2006-11-02
End: 2011-02-25

CAVD 287
CAVD 287 is an immunogenicity study to evaluate and characterize the neutralization activity of broadly neutralizing antibodies in HIV controllers.

No data is available for this study.

Antibody Screening
Non-Organism Study

David Ho
Ho: Enhancing Innate Immune Activation

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2003-12-18
End: 2011-02-25

CAVD 288
CAVD 288 is a preclinical rabbit study to assess a novel gp41 construct (HA-gp41) for its ability to induce neutralizing antibodies in rabbits.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

Product info coming soon!

Inactive
Start: 2007-10-25
End:

CAVD 289
CAVD 289 isolated llama VHH antibody fragments from llamas immunized with HIV-1 ENV proteins. The VHH were selected for targeting the CD4 binding site.

NAb MAb

Antibody Production
Llama

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Prophylactic neutralizing Ab

Product info coming soon!

Inactive
Start: 2007-11-27
End: 2012-08-30

CAVD 290
CAVD 290 is an immunogenicity study to evaluate and characterize the neutralization activity of broadly neutralizing antibodies from humans in HIV controllers.

No data is available for this study.

Antibody Screening
Non-Organism Study

David Ho
Ho: Enhancing Innate Immune Activation

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2007-09-05
End: 2011-02-25

CAVD 291
CAVD 291 is an antibody production study using ZM96 gp140 as an immunogen to raise neutralizing monoclonal antibodies in humanized Ig mice.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Prophylactic neutralizing Ab

Product info coming soon!

Inactive
Start: 2008-03-27
End: 2012-04-04

CAVD 292
CAVD 292 is a preclinical rabbit study to evaluate neutralization activity of Clade C consensus C3 and V4 peptide/adjuvant prime/boost regimens.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

David Ho
Ho: Enhancing Innate Immune Activation

Protein & peptide vaccines

CFA
IFA
Clade C V3 peptide

Inactive
Start: 2008-01-18
End: 2011-02-25

CAVD 293
CAVD 293 is an immunogenicity study of antibody-like molecules.

No data is available for this study.

Antibody Screening
Non-Organism Study

Leo Stamatatos
Stamatatos: Novel HIV Immunogen Vaccines

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2008-04-22
End: 2012-11-28

CAVD 294
CAVD 294 is a non-human primate study comparing different doses and routes in BCG/Ad5 prime/boost regimens. A follow up boost study (CAVD 267) was performed.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Norman Letvin
Letvin: rAdenoviral & rMycobacterial Vector Immunogens

Vector vaccines (viral or bacterial)

rAd5-SIV
rBCG Pasteur

Inactive
Start: 2009-10-20
End: 2012-04-10

CAVD 295
CAVD 295 is a rabbit study assessing several first generation antigens for ability to generate broadly neutralising antibodies.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

Saline (non-specific)
CFA
IFA
ZM96 gp140
2F5/4E10 mimotope
gp41 Mod
gp41 N

Inactive
Start: 2008-05-22
End: 2011-04-18

CAVD 296
CAVD 296 is a rabbit study designed to assess carbopol at ph4 and ph7 compared to FCA/FIA and to optimize dose of antigen (Chinese clade C HIV-1 CN54)

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

Saline (non-specific)
CFA
IFA
ZM96 gp140
Carbopol (pH 4)
Carbopol (pH 7)

Inactive
Start: 2008-09-24
End: 2011-06-21

CAVD 297
CAVD 297is a rabbit study assessing 2 newly isolated HIV strains for immunizing potential, in comparison with CN54 gp140. The combination of 3 strains was most effective. One of the new strains was more effective than CN54.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

CFA
IFA
ZM96 gp140
gp140 UG37
gp140 BX08

Inactive
Start: 2008-09-24
End: 2011-06-21

CAVD 298
CAVD 298 is a preclinical rabbit study comparing protein and adjuvant regimens administered by subcutaneous and intravaginal routes.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Protein & peptide vaccines

ZM96 gp140

Inactive
Start: 2008-12-16
End: 2011-02-25

CAVD 299
CAVD 299 (CAVD 362) is an immunogenicity study to evaluate and characterize the neutralization activity of broadly neutralizing antibodies in HIV controllers.

No data is available for this study.

Antibody Screening
Non-Organism Study

David Ho
Ho: Enhancing Innate Immune Activation

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2007-12-14
End: 2012-07-17

CAVD 300
CAVD 300 is an immunogenicity study to evaluate and characterize the neutralization activity in serum from a panel of HIV-infected individuals.

No data is available for this study.

Antibody Screening
Non-Organism Study

David Ho
Ho: Enhancing Innate Immune Activation

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2009-06-02
End:

CAVD 301
CAVD 301 is a preclinical mouse study to evaluate and compare the neutralization activity following peptide and DNA prime/boost regimens.

No data is available for this study.

Pre-Clinical Non-NHP
Mouse

David Ho
Ho: Enhancing Innate Immune Activation

Combo: DNA & protein vaccines

Product info coming soon!

Active
Start: 2009-02-25
End:

CAVD 302
CAVD 302 is a preclinical rabbit study of protein and adjuvant regimens.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Leo Stamatatos
Stamatatos: Novel HIV Immunogen Vaccines

Protein & peptide vaccines

SF162 gp140
gp140 Q168
gp140 Q259
gp140 Q461
SF162NL gp140
T88 gp140

Inactive
Start: 2009-07-29
End: 2011-09-30

CAVD 303
CAVD 303 is a non-human primate study comparing DNA/protein prime/boost regimens with a conformationally constrained gp120 immunogen, rhFLSC.

NAb

Pre-Clinical NHP
Rhesus macaque

Robert Gallo
Gallo: Systemic, Mucosal & Passive Immunity

Combo: DNA & protein vaccines

rhFLSC Protein
rhFLSC DNA
GLA-SE (IDRI-EM005)
A1-Vector

Inactive
Start: 2009-07-27
End: 2012-02-24

CAVD 304
CAVD 304 is a non-human primate study comparing intravaginal and intramuscular routes of administration of a protein and adjuvant regimen.

NAb

Pre-Clinical NHP
Cynomolgus macaque

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Protein & peptide vaccines

HIV-1 gp140
Carbopol 974P
GSK AS01

Inactive
Start: 2009-06-10
End: 2011-09-30

CAVD 305
CAVD 305 is a preclinical rabbit study comparing protein and adjuvant regimens administered by the intradermal route.

NAb

Pre-Clinical Non-NHP
Rabbit

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Protein & peptide vaccines

PEI
CN54env-gp140
ZM96 gp140
Wax particles

Inactive
Start: 2009-11-13
End: 2011-09-30

CAVD 306
CAVD 306 is an immunogenicity study to screen broadly neutralizing antibodies from a cohort of HIV infected individuals in Ndola, Zambia.

No data is available for this study.

Antibody Screening
Non-Organism Study

Barton Haynes
Haynes: Broad Neutralizing Antibody Consortium

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2008-11-03
End: 2010-04-23

CAVD 307
CAVD 307 (CAVIMC 026) is an immunogenicity study of CD8 T-Cells.

No data is available for this study.

Non-Clinical Immunogenicity
Non-Organism Study

Giuseppe Pantaleo
Pantaleo: Poxvirus-Based Vaccine Development

NA

No Products used in study

Inactive
Start: 2010-01-04
End: 2010-07-19

CAVD 308
CAVD 308 is an immunogenicity study comparing immune responses in subjects with NAbs against primary HIV-1 A/C/CRF02_AG strains.

No data is available for this study.

Antibody Screening
Non-Organism Study

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2010-01-18
End: 2011-08-16

CAVD 309
CAVD 309 is an immunogenicity study to assess the potency and breadth of the monoclonal antibody, Ibalizumab, against a diverse Env-pseudotype panel.

NAb MAb

Antibody Screening
Non-Organism Study

David Ho
Ho: Ibalizumab for HIV Prevention

Prophylactic neutralizing Ab

Ibalizumab

Inactive
Start: 2009-12-16
End: 2010-06-22

CAVD 310
CAVD 310 is a non-human primate study comparing administration of the monoclonal antibody, Ibalizumab, via intravenous and subcutaneous routes.

NAb, NAb MAb

Pre-Clinical NHP
Rhesus macaque

David Ho
Ho: Ibalizumab for HIV Prevention

Prophylactic neutralizing Ab

Ibalizumab

Inactive
Start: 2009-12-28
End:

CAVD 311
CAVD 311 is an immunogenicity study of broadly neutralizing antibodies in an East London cohort infected with diverse clades of HIV-1.

No data is available for this study.

Antibody Screening
Non-Organism Study

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2010-01-18
End: 2010-08-05

CAVD 312
CAVD 312 is a preclinical rabbit study assessing combined HIV strains for immunizing potential in different adjuvants, in comparison with each strain alone. Modest neutralization was found with Freunds adjuvant in comparison to TLR agonists.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

Carbopol 974P
TLR4/7
TLR4
CFA
IFA
TLR
gp140 UG37
gp140 BX08
CN54rgp140 protein
gp140 BR29

Inactive
Start: 2009-09-11
End: 2011-08-08

CAVD 313
CAVD 313 is a preclinical rabbit study to further investigate the neutralizing antibodies elicited by modifications to the gp41 membrane proximal region of HIV env.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

CFA
IFA
CN54env-gp140
gp41 5HB
gp41 CC
gp41 D
gp41 HR1
gp41 SS

Inactive
Start: 2011-04-12
End: 2011-08-08

CAVD 314
CAVD 314 is a preclinical rabbit study investigating several prime-boost regimens in which HIV env gp160 protein and modified gp41 constructs were boosted with virus-like particles containing the corresponding modified gp41 proteins.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Combo: DNA, protein & VLP vaccines

CFA
IFA
CN54env-gp140
CTM-2F5
CTM
CTM-H3
CTM-GCN-gp41
ZM96
GCN-gp41 FD
VLP-GCN-gp41 CTM
VLP-H3 CTM
VLP-gp41 CTM

Inactive
Start: 2011-04-12
End: 2011-08-08

CAVD 315
CAVD 315 is a preclinical rabbit study investigating several prime-boost regimens in which plasmid DNA (HIV gag) or env gp160 and gp41 proteins were boosted with mimotope from the env gp41 region with cholera toxin B as an immune stimulator.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Combo: DNA, protein & vector vaccines

CFA
IFA
CN54env-gp140
CN54env-gp145
CTM-2F5
R2env-gp140
VLP-CTB
VLP-CTB mimotope
VLP-GAG
VLP-R2
pCDNA-R2
pCDNA-gag

Inactive
Start: 2010-03-23
End: 2011-08-08

CAVD 316
CAVD 316 is a preclinical mouse study to evaluate the neutralization activity of sera collected from mice immunized with dendritic cell-targeted HIV env gp120 given along with polyICLC or GLA as adjuvant.

NAb

Pre-Clinical Non-NHP
Mouse

Sarah Schlesinger
Steinman: Dendritic Cells & Flavivirus Vectors

Prophylactic neutralizing Ab

GLA
Poly ICLC
DEC-HIV env gp120
DEC antibody

Inactive
Start: 2010-05-04
End: 2011-05-13

CAVD 317
CAVD 317 (NYU-9) is a preclinical rabbit study to evaluate and compare the neutralization activity of sera following DNA/protein prime/boost regimens.

NAb

Pre-Clinical Non-NHP
Rabbit

Susan Zolla-Pazner
Zolla-Pazner: Epitope-Scaffold Immunogens

Combo: DNA & protein vaccines

DNA (gp120.C1-opt)
V3/3074 CTB
V3/H CTB
V3/2219 CTB
V3/B

Inactive
Start: 2010-04-05
End: 2012-03-20

CAVD 318
CAVD 318 is a preclinical rat study characterizing novel MPER antigens for ability to generate broadly neutralizing antibodies. High anti-peptide titers were produced, but there was no detectable neutralization.

No data is available for this study.

Pre-Clinical Non-NHP
Rat

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

Product info coming soon!

Inactive
Start: 2010-05-12
End: 2012-02-14

CAVD 319
CAVD 319 is a preclinical rabbit study assessing 3 newly isolated HIV strains for immunizing potential, in comparison with CN54 gp140. None of the new strains proved as immunogenic as CN54.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

Product info coming soon!

Inactive
Start: 2008-09-24
End: 2011-08-08

CAVD 320
CAVD 320 is a preclinical rabbit study to evaluate the neutralizing activity following a Clade C Consensus V3 subunit peptide and adjuvant regimen.

NAb

Pre-Clinical Non-NHP
Rabbit

David Ho
Ho: Enhancing Innate Immune Activation

Protein & peptide vaccines

CFA
IFA
Clade C C3 peptide
Clade C V4 peptide

Inactive
Start: 2010-07-14
End: 2010-12-28

CAVD 321
CAVD 321 is a preclinical mouse study of DNA and protein regimens.

No data is available for this study.

Pre-Clinical Non-NHP
Mouse

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Combo: DNA & protein vaccines

CN54gp140 DNA
ZM96gp140 DNA
CN54rgp140 protein

Inactive
Start: 2008-11-25
End: 2010-12-28

CAVD 322
CAVD 322 is a preclinical mouse study to see if primed SIV gag-specific T cells would help generate a neutralizing antibody response to SIV envelope in mice immunized with two doses of a DC-targeted SIV protein gag p27 based vaccine to induce SIV gag p27 specific help.

No data is available for this study.

Pre-Clinical Non-NHP
Mouse

Sarah Schlesinger
Steinman: Dendritic Cells & Flavivirus Vectors

Prophylactic neutralizing Ab

Poly ICLC
AT-2 SIV
DEC-SIV gag

Inactive
Start: 2010-03-02
End: 2010-12-16

CAVD 323
CAVD 323 is a non-human primate challenge study comparing DNA, MVA, and protein prime/boost regimens.

NAb

Pre-Clinical NHP
Rhesus macaque

David Montefiori
Montefiori: VIMC

Combo: DNA, protein & vector vaccines

MVA-SIV-Gag-Pol
MVA-HIV-Gag-Pol
DNA-SIV-Gag-Pol
DNA-HIV-E
MVA-HIV-E
oligomeric CM235 Env
SHIV E
Ras3C
Bupivacaine

Inactive
Start: 2010-09-10
End: 2011-09-15

CAVD 324
CAVD 324 is a preclinical rabbit study to evaluate neutralization activity after repeated doses of HIV envelope DNA administered via electroporation.

NAb

Pre-Clinical Non-NHP
Rabbit

David Ho
Ho: Enhancing Innate Immune Activation

DNA vaccines

gp120 DNA
gp160 DNA
gp120 Core-Fc DNA
gp120 Core DNA

Inactive
Start: 2010-09-21
End: 2011-08-16

CAVD 325
CAVD 325 is a rabbit study investigating whether alternating adjuvants in a single regimen triggers a higher quality neutralizing antibody response. However, no unusually potent or broad neutralization was observed.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

PEI
Carbopol
CN54rgp140 protein

Inactive
Start: 2010-08-10
End: 2010-12-28

CAVD 326
CAVD 326 is a preclinical rabbit study to evaluate the immunogenicity of soluble, collagen-stabilized trimeric gp120 constructs derived from the clade A Env Q259d2.17.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Leo Stamatatos
Stamatatos: Novel HIV Immunogen Vaccines

Protein & peptide vaccines

PEI
QS-21
recP

Inactive
Start: 2010-08-18
End: 2011-01-31

CAVD 327
CAVD 327 is an immunogenicity study of broadly neutralizing antibodies which evaluates the antibody responses elicited by V3 mimetics in rabbits.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

TLR4/7
CFA
IFA
gp140 UG37
CN54rgp140 protein
gp140 BR29
V3 cyclic peptide
V3 peptide-KLH
V3 peptide-Truncated

Inactive
Start: 2010-10-04
End: 2011-06-21

CAVD 328
CAVD 328 is an immunogenicity comparing two (2) adjuvants ("P" and "C") formulated with 100ug of GMP prepared ZM96 (clade C ag140) in a rabbit model.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

Product info coming soon!

Inactive
Start: 2008-02-12
End:

CAVD 329
CAVD 329 is a continuation of CAVD 289. Both studies isolated llama VHH antibody fragments from llamas immunized with HIV-1 ENV proteins. The VHH were selected for targeting the CD4 binding site.

NAb MAb

Antibody Production
Llama

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Prophylactic neutralizing Ab

Product info coming soon!

Inactive
Start: 2010-10-27
End: 2011-11-15

CAVD 330
CAVD 330 is an immunogenicity study evaluating the directing of the immune response to well-defined HIV-1 envelope epitopes using the mucosal adjuvant Cholera toxin B as carrier.

No data is available for this study.

Pre-Clinical Non-NHP
Mouse

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Combo: DNA & protein vaccines

gp41 DNA
CTB-MPER

Inactive
Start: 2010-02-09
End: 2011-08-16

CAVD 331
CAVD 331 is a preclinical mouse study of monoclonal antibody and protein regimens.

NAb

Pre-Clinical Non-NHP
Mouse

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Combo: Protein & prophylactic Ab

CN54rgp140 protein
3D6 mAb
mAb (non-env-specific)

Inactive
Start: 2011-02-02
End: 2011-10-19

CAVD 332
CAVD 332 is a immunogenicity study of monoclonal antibodies.

No data is available for this study.

Antibody Production
Plant

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2011-03-16
End: 2011-10-19

CAVD 333
CAVD 333 is an immunogenicity study evaluating the potential use of SIV Env in generating neutralizing antibodies against HIV-1.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Combo: DNA & protein vaccines

Product info coming soon!

Inactive
Start: 2011-03-10
End: 2012-02-14

CAVD 334
CAVD 334 is a preclinical mouse study to evaluate and compare neutralization activity following HIV-1 envelope protein and adjuvant regimens.

No data is available for this study.

Pre-Clinical Non-NHP
Mouse

David Ho
Ho: Enhancing Innate Immune Activation

Protein & peptide vaccines

Product info coming soon!

Inactive
Start: 2010-03-25
End: 2011-10-11

CAVD 335
CAVD 335 is a non-human primate study to evaluate the pharmacokinetics and mucosal site trafficking of a systemically-infused monoclonal antibody.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Barton Haynes
Haynes: Broad Neutralizing Antibody Consortium

Prophylactic neutralizing Ab

11.31 mAb

Inactive
Start: 2010-06-06
End: 2012-06-03

CAVD 336
CAVD 336 is a preclinical sheep study comparing protein and adjuvant regimens.

No data is available for this study.

Antibody Production
Sheep

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Prophylactic neutralizing Ab

Product info coming soon!

Inactive
Start: 2011-01-12
End: 2011-10-19

CAVD 337
CAVD 337 (VRC01) is an immunogenicity study of monoclonal antibodies.

No data is available for this study.

Antibody Screening
Non-Organism Study

David Montefiori
Montefiori: VIMC

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2010-03-11
End: 2011-10-11

CAVD 338
CAVD 338 (NYU-10) is a preclinical rabbit study to evaluate and compare the neutralization activity of sera following DNA/protein prime/boost regimens.

NAb

Pre-Clinical Non-NHP
Rabbit

Susan Zolla-Pazner
Zolla-Pazner: Epitope-Scaffold Immunogens

Combo: DNA & protein vaccines

DNA-C-Env
V3/C
V3/3074
V3/H
V3/2219

Inactive
Start: 2010-07-26
End: 2012-03-20

CAVD 339
CAVD 339 (NYU-8) is an immunogenicity study to evaluate and screen the neutralization activity of monoclonal antibodies isolated from rabbits following immunization.

No data is available for this study.

Antibody Screening
Non-Organism Study

Susan Zolla-Pazner
Zolla-Pazner: Epitope-Scaffold Immunogens

Prophylactic neutralizing Ab

Product info coming soon!

Inactive
Start: 2009-09-22
End: 2012-03-20

CAVD 340
CAVD 340 is a preclinical guinea pig study to evaluate the neutralization activity following immunization with transmitted Env 040, 089, 086.

No data is available for this study.

Pre-Clinical Non-NHP
Guinea Pig

Barton Haynes
Haynes: Broad Neutralizing Antibody Consortium

Protein & peptide vaccines

Product info coming soon!

Inactive
Start: 2009-11-10
End: 2011-11-16

CAVD 341
CAVD 341 is an immunogenicity study of broadly neutralizing antibodies evaluating gp41 MPER based liposomes in inducing neutralizing antibodies.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Combo: DNA & protein vaccines

Carbopol
R2-gp145 DNA
gp41-FD liposome
gp41-CHRTM liposome
C-terminal-Cys liposome
Empty liposome
R2 protein

Inactive
Start: 2010-10-04
End: 2012-02-14

CAVD 342
CAVD 342 is a preclinical guinea pig study investigating different prime-boost combinations of gp41-HR1 liposomes or peptide mimetics compared to control immunizations (R2 (Clade B), CN54 (Clade C) or SF162 (Clade B) gp140s.

NAb

Pre-Clinical Non-NHP
Guinea Pig

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

PEI
CN54env-gp140
R2env-gp140
gp41 5HB
gp41 HR1
SF162env-gp140
SYM767
SYM997

Inactive
Start: 2011-02-10
End: 2012-02-14

CAVD 343
CAVD 343 is preclinical rabbit study evaluating efficiency of DNA delivery by electroporation comparing IM electroporation of R2env-gp145 with IM administration of R2env-gp140 protein.

NAb

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Combo: DNA & protein vaccines

R2env-gp140
R2-gp145 DNA
Hiltonol

Inactive
Start: 2011-03-10
End: 2012-02-14

CAVD 344
CAVD 344 is preclinical rabbit study comparing two (2) adjuvants in the ability to enhance antibody responses.

NAb

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Combo: DNA & protein vaccines

PEI
Poly IC
CFA
IFA
R2env-gp140
R2-gp145 DNA

Inactive
Start: 2011-03-10
End: 2012-02-14

CAVD 345
CAVD 345 is preclinical rabbit study of broadly neutralizing antibodies where an adjuvant comparison is conducted using SF162-gp140 and different adjuvant combinations.

NAb

Pre-Clinical Non-NHP
Rabbit

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

MF59
PEI
Carbopol 974P
CFA
IFA
SF162 gp140
Carbopol 971

Inactive
Start: 2011-03-04
End: 2012-05-16

CAVD 346
CAVD 346 is an antigen comparison study in Guinea Pigs using env gp140 from elite neutralisers and structural modifications to increase immunogenicity.

No data is available for this study.

Pre-Clinical Non-NHP
Guinea Pig

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

Env gp140 AN439856-impol
Env gp140 AN439856-regen
Env gp140 CA018-imcam
Env gp140 CA018-impol
Env gp140 CA018-regen
Env gp140 CN54-impol
Env gp140 HK20-imcam
Env gp140 K530-regen
Env gp140 R2-regen
Env gp140 R2GCN-usuhs
Env gp140 R2ditri-usuhs
Env gp140 R2linkGCN-usuhs
Env gp140 SF162-novar
Env gp140 TV1-novar
Env gp140 UG37-impol
Env gp140 UG37-oxfor
Env gp140 UG37-regen

Inactive
Start: 2011-03-01
End: 2012-02-14

CAVD 347
CAVD 347 is an immunogenicity study of novel neutralizing monoclonal human anti-HIV-1 envelope monoclonal antibodies isolated from HIV-1 controllers.

No data is available for this study.

Antibody Screening
Non-Organism Study

Robert Gallo
Gallo: Systemic, Mucosal & Passive Immunity

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2009-03-10
End: 2012-07-16

CAVD 351
CAVD 351 is a non-human primate challenge study comparing full-length single chain DNA/Protein/adjuvant regimens administered via electroporation.

NAb

Pre-Clinical NHP
Rhesus macaque

Robert Gallo
Gallo: Systemic, Mucosal & Passive Immunity

Combo: DNA & protein vaccines

rhFLSC 'A' Protein
rhFLSC 'B' Protein
rhFLSC 'A' DNA
rhFLSC 'B' DNA
GLA-SE (IDRI-EM005)
SHIV162p3
IL-12
Placebo DNA

Inactive
Start: 2012-02-29
End: 2016-03-30

CAVD 353
CAVD 353 is a monoclonal antibody characterization study to evaluate the neutralization activity of the monoclonal antibody, Ibalizumab, and Ibalizumab variants.

NAb MAb

Antibody Screening
Non-Organism Study

David Ho
Ho: Ibalizumab for HIV Prevention

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-03-01
End: 2013-02-13

CAVD 354
CAVD 354 is a non-human primate study of protein and adjuvant regimens, comparing rhFLSC antigen versus gp120 in RC529 and Iscomatrix adjuvants.

BAMA

Pre-Clinical NHP
Rhesus macaque

Robert Gallo
Gallo: Systemic, Mucosal & Passive Immunity

Protein & peptide vaccines

rhFLSC Protein
SHIV162p3
RC529
Iscomatrix
gp120
None

Inactive
Start: 2012-03-09
End: 2014-12-22

CAVD 355
CAVD 355 (CAVIMC-045) is a non-human primate study of protein and adjuvant regimens.

BAMA, NAb

Pre-Clinical NHP
Rhesus macaque

Julie McElrath
McElrath: Innate to Adaptive Immunity

Protein & peptide vaccines

HIV-1 CN54 gp140
SIV p55 gag
PLGA (MPL)
PLGA (R848)

Inactive
Start: 2012-03-09
End: 2016-10-21

CAVD 358
CAVD 358 is an immunogenicity study of sera and monoclonal antibodies from infected macaques.

No data is available for this study.

Antibody Production
Non-Organism Study

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-03-26
End: 2012-09-05

CAVD 359
CAVD 359 is an immunogenicity study to identify patients with broadly neutralizing serum activity against HIV.

No data is available for this study.

Antibody Screening
Non-Organism Study

Michel Nussenzweig
Nussenzweig: Discovery & Characterization of bNAbs

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-03-26
End: 2017-02-24

CAVD 360
CAVD 360 is an immunogenicity study to define the epitopes recognized by a panel of anti-gp41 monoclonal antibodies that mediate ADCC.

No data is available for this study.

Antibody Screening
Non-Organism Study

George Lewis
Lewis: Ab Specificity & Fc-Mediated Protection

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-04-03
End: 2014-10-22

CAVD 361
CAVD 361 (CAVIMC-041, C0692-11) is a preclinical rabbit study to compare the immunogenicity and induction of neutralizing antibodies to gp120 Env proteins discordant for binding to the PG9 broadly neutralizing antibody.

NAb

Pre-Clinical Non-NHP
Rabbit

Michael Caulfield
Third party request

Combo: DNA & protein vaccines

Iscomatrix
IAVI A1 gp120 DNA
IAVI A1 gp120 Protein
WT 16936 gp120 DNA
WT 16936 gp120 Protein
16936-V55 chimera gp120 DNA
16936-V55 chimera gp120 Protein
16055-V36 chimera gp120 DNA
16055-V36 chimera gp120 Protein
16055 gp120 DNA
16055 gp120 Protein
Control DNA

Inactive
Start: 2012-04-04
End: 2012-08-14

CAVD 363
CAVD 363 (NHP#45) is a non-human primate study to evaluate and compare the immunogenicity of Clade B, CON-S, and Mosaic Env DNA and NYVAC prime/boost regimens.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Barton Haynes
Haynes: Centralized Envelope Phase I Study

Combo: DNA & vector vaccines

DNA-B-Env
DNA Mosaic Env
DNA-Con S-Env
NYVAC-Con S-Env
NYVAC-Mosaic-Env
NYVAC-B-Env

Inactive
Start: 2012-04-30
End: 2014-01-24

CAVD 364
CAVD 364 is a non-human primate study of ALVAC-HIV (vCP1521) and AIDSVAX B/E prime/boost regimens.

NAb

Pre-Clinical NHP
Rhesus macaque

Norman Letvin
Letvin: rAdenoviral & rMycobacterial Vector Immunogens

Combo: Protein & vector vaccines

ALVAC (vCP1521)
AIDSVAX B/E
Placebo ALVAC

Inactive
Start: 2012-05-01
End: 2015-06-19

CAVD 366
CAVD 366 is an immunogenicity study to characterize IgA and IgG antibodies with ADCC activity in a chronically HIV-infected Clade B cohort.

No data is available for this study.

Antibody Screening
Non-Organism Study

George Lewis
Lewis: Ab Specificity & Fc-Mediated Protection

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-05-15
End: 2014-10-06

CAVD 367
CAVD 367 is a preclinical guinea pig study investigating Virus-Like Particles (VLP) (Env alone and ENV-Gag) derived from ZM96, in comparison to ZM96 gp140.

No data is available for this study.

Pre-Clinical Non-NHP
Guinea Pig

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Combo: Protein & VLP vaccines

Product info coming soon!

Inactive
Start: 2012-05-17
End: 2013-03-21

CAVD 369
CAVD 369 is an immunogenicity study using samples from 2 non-human primate trimer studies.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Protein & peptide vaccines

GLA-AF
CN54 gp140
MF59
R848
SF162
TV-1 C

Inactive
Start: 2012-06-03
End: 2013-10-30

CAVD 370
CAVD 370 is an immunogenicity study of monoclonal antibodies.

NAb MAb

Antibody Screening
Non-Organism Study

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-06-06
End: 2013-02-11

CAVD 371
CAVD 371 (AUP 512) is a non-human primate study comparing DNA/protein and NYVAC/protein prime/boost regimens.

BAMA, ICS, NAb

Pre-Clinical NHP
Rhesus macaque

Giuseppe Pantaleo
Pantaleo: Poxvirus-Based Vaccine Development

Combo: DNA, protein & vector vaccines

MF59
NYVAC-C-Gag-Pol-Nef
NYVAC-C-gp140
DNA-C
gp120 C.1086
gp120 TV1

Inactive
Start: 2012-06-20
End: 2016-11-10

CAVD 373
CAVD 373 is an immunogenicity study to evaluate and characterize the neutralization activity of antibodies from HIV infected individuals.

No data is available for this study.

Antibody Screening
Non-Organism Study

David Ho
Ho: Enhancing Innate Immune Activation

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-06-29
End: 2012-07-06

CAVD 374
CAVD 374 is an immunogenicity study to identify and characterize monoclonal antibodies from vaccine recipients in the human clinical trial, RV144.

No data is available for this study.

Antibody Screening
Non-Organism Study

Barton Haynes
Haynes: B-Cell Lineage Envelope Design

Prophylactic neutralizing Ab

ALVAC (vCP1521)
AIDSVAX B/E
Saline (non-specific)
Placebo ALVAC
Placebo AIDSVAX B/E

Inactive
Start: 2012-07-06
End: 2016-01-15

CAVD 375
CAVD 375 is an immunogenicity study to isolate and evaluate IgA antibodies using specimens from vaccine recipients in the human clinical trial, RV144.

NAb MAb

Antibody Screening
Non-Organism Study

Barton Haynes
Haynes: Role of IgA in HIV-1 Protection

Prophylactic neutralizing Ab

ALVAC (vCP1521)
AIDSVAX B/E
Saline (non-specific)
Placebo ALVAC
Placebo AIDSVAX B/E

Inactive
Start: 2012-07-13
End: 2016-01-15

CAVD 376
CAVD 376 is an immunogenicity study to screen monoclonal antibodies from vaccine recipients in the human clinical trials, RV144, RV305, and RV306.

No data is available for this study.

Antibody Screening
Non-Organism Study

Barton Haynes
Haynes: B-Cell Lineage Envelope Design

Prophylactic neutralizing Ab

ALVAC (vCP1521)
AIDSVAX B/E
Saline (non-specific)
Placebo ALVAC
Placebo AIDSVAX B/E

Inactive
Start: 2012-07-20
End: 2016-02-16

CAVD 378
CAVD 378 is a monoclonal antibody screening study to evaluate the quality of gp120-specific antibody responses elicited by different glycan processed gp120s​.

No data is available for this study.

Antibody Screening
Non-Organism Study

Shan Lu
Lu: Creating a Better Envelope

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-08-16
End: 2014-10-22

CAVD 379
CAVD 379 describes and characterizes anti-HIV llama antibodies (VHHs) induced in multiple immunisations. Three new VHH were identified that can bind the resurfaced core gp120 used to isolate the broadly neutralising human VRC01 antibody.

NAb MAb

Antibody Screening
Non-Organism Study

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Prophylactic neutralizing Ab

Product info coming soon!

Inactive
Start: 2012-08-16
End: 2013-08-02

CAVD 380
CAVD 380 (CAVIMC-046) is a non-human primate study comparing Clade A, B, and C protein regimens.

NAb

Pre-Clinical NHP
Rhesus macaque

Leo Stamatatos
Stamatatos: Novel HIV Immunogen Vaccines

Protein & peptide vaccines

Saline (non-specific)
PEI
gp120 B QH0692
gp120 B QH0692 resurfaced
gp140 A/B
gp140 C
MPL
R848

Inactive
Start: 2012-08-28
End: 2013-04-04

CAVD 384
CAVD 384 is an immunogenicity study of samples from 2 NHP studies using gp140 trimers.

No data is available for this study.

Pre-Clinical NHP
Cynomolgus macaque

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Protein & peptide vaccines

GLA
CN54 gp140
MF59
R848
SF162
TV-1 C

Inactive
Start: 2012-08-29
End: 2015-10-19

CAVD 385
CAVD 385 is an immunogencity study to evaluate various engineered forms of broadly neutralizing antibodies (bNAbs) across large viral panels.

No data is available for this study.

Antibody Screening
Non-Organism Study

Pamela Bjorkman
Bjorkman: Improving Potency and Breadth of Natural bNAbs

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-08-30
End: 2015-10-19

CAVD 386
CAVD 386 is a preclinical guinea pig study investigating in vivo survival of, and complement binding by, Env antigen, in protein/adjuvant regimens.

No data is available for this study.

Pre-Clinical Non-NHP
Guinea Pig

Michael Frank
Frank: Studies to Maximize Immunogenicity

Protein & peptide vaccines

Product info coming soon!

Inactive
Start: 2012-08-31
End: 2013-04-02

CAVD 388
CAVD 388 is an immunogenicity study of the potency and breadth of a variety of reagents containing different architectures and binding fragments.

No data is available for this study.

Antibody Screening
Non-Organism Study

Pamela Bjorkman
Bjorkman: Improving Potency and Breadth of Natural bNAbs

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-09-19
End: 2012-10-26

CAVD 389
CAVD 389 is a preclinical rabbit study to evaluate the quality of gp120-specific antibody responses elicited by different glycan processed gp120s following DNA/protein prime/boost regimens.​

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Shan Lu
Lu: Creating a Better Envelope

Combo: DNA & protein vaccines

Product info coming soon!

Inactive
Start: 2012-09-24
End: 2013-05-23

CAVD 390
CAVD 390 is an immunogenicity study comparing antiviral molecule responses to develop a Lactobacillus based microbicide that can be applied vaginally or rectally that effectively blocks HIV transmission during intercourse.

No data is available for this study.

Antibody Production
Non-Organism Study

Timothy Fouts
Third party request

Prophylactic neutralizing Ab

Product info coming soon!

Inactive
Start: 2012-09-26
End: 2013-02-11

CAVD 391
CAVD 391 is a non-human primate challenge study of a prime/boost regimen using an ALVAC-HIV viral vector (vCP1521), rhFLSC protein, and adjuvant.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Robert Gallo
Gallo: FLSC Phase I & II Clinical Trials

Combo: Protein & vector vaccines

rhFLSC Protein
ALVAC (vCP1521)
GLA-SE (IDRI-EM005)
SHIV162p3
Placebo ALVAC

Inactive
Start: 2012-11-01
End: 2015-02-03

CAVD 392
CAVD 392 is a non-human primate study to evaluate and compare the immunogenicity of different adjuvants in combination with the immunogen, rhFLSC.

ICS, ELISpot, NAb

Pre-Clinical NHP
Rhesus macaque

Robert Gallo
Gallo: FLSC Phase I & II Clinical Trials

Protein & peptide vaccines

rhFLSC Protein
Alum
IDRI EM001
GLA-SE (IDRI-EM005)
Alum/GLA
None

Inactive
Start: 2012-11-01
End: 2015-02-03

CAVD 393
CAVD 393 is a non-human primate challenge study comparing protein regimens.

NAb

Pre-Clinical NHP
Rhesus macaque

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Protein & peptide vaccines

MF59
gp120 V1/V2 A244
Carbopol 974P
gp120 V3 CN54
gp140 CA18
gp41 HXB2
SHIV-SF162P3

Inactive
Start: 2012-11-19
End: 2014-10-06

CAVD 394
CAVD 394 is a non-human primate study to evaluate the neutralization activity of a regimen using a C1 peptide and the adjuvants, MF59, TLR7, and TLR9.

NAb

Pre-Clinical NHP
Rhesus macaque

Barton Haynes
Haynes: Role of IgA in HIV-1 Protection

Protein & peptide vaccines

MF59
TLR7
C1 peptide
TLR9

Inactive
Start: 2012-11-19
End: 2013-05-21

CAVD 398
CAVD 398 is a preclinical rabbit study to compare immunogenicity of vaccinia viral vector/N197 Glycan Modification Env protein prime/boost regimens.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Shiu-Lok Hu
Hu: Unmasking Conserved Epitopes

Combo: Protein & vector vaccines

Alum
v-NY-89.6 WT Env gp160
v-NY-89.6 N197Q Env gp160
Env gp160 WT
Env gp160 N197Q
Env gp120 N197Q
Env gp120 WT

Inactive
Start: 2012-11-30
End: 2014-05-09

CAVD 399
CAVD 399 is an antibody screening study which isolated and characterized a MPER-specific single chain antibody (VHH) that neutralized various sensitive and resistant HIV-1 strains, as well as SHIV strains in TZM-bl cells.

NAb MAb

Antibody Screening
Non-Organism Study

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Prophylactic neutralizing Ab

Product info coming soon!

Inactive
Start: 2012-11-30
End: 2013-05-23

CAVD 400
CAVD 400 is a monoclonal antibody screening study.

No data is available for this study.

Antibody Screening
Non-Organism Study

Robin Weiss
Weiss: Protection by Neutralizing Antibodies

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-12-05
End: 2013-11-08

CAVD 401
CAVD 401 is a preclinical rabbit study comparing CN54gp140 DNA and protein regimens administered via intramuscular, intradermal, and subcutaneous routes.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Combo: DNA & protein vaccines

Product info coming soon!

Inactive
Start: 2012-12-14
End: 2013-07-25

CAVD 402
CAVD 402 is a monoclonal antibody screening study evaluating evolution from non-neutralizing to broadly neutralizing antibody responses in chronically infected individuals.

NAb MAb

Antibody Screening
Non-Organism Study

Bruce Walker
Walker: bNabs after Infection and Immunization

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2012-12-21
End: 2013-10-16

CAVD 403
CAVD 403 is an immunogenicity study of neutralizing antibodies examining neutralization activities induced by Man5 Env (from Pichia pastoris) and CHO-Env.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Shan Lu
Lu: Creating a Better Envelope

Protein & peptide vaccines

Product info coming soon!

Inactive
Start: 2013-01-02
End: 2015-02-26

CAVD 404
CAVD 404 is preclinical rabbit study evaluating neutralization activities induced in rabbits by DNA prime-protein boost vs. co-delivery of DNA and protein.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Shan Lu
Lu: Creating a Better Envelope

Combo: DNA & protein vaccines

Product info coming soon!

Inactive
Start: 2013-01-02
End: 2015-02-26

CAVD 405
CAVD 405 (NHP Study P162) is a non-human primate challenge study of ALVAC/protein prime/boost regimens.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Genoveffa Franchini
Third party request

Combo: Protein & vector vaccines

Alum
MF59
SIVmac251
None
gD-766gp120
gD-CG7Vgp120
ALVAC parental
ALVAC-SIV 766 Gag-pro-SIV 766gp120-TM
ALVAC-SIV K6W
SC 766
SC CG7V
SIV mac251 protein

Inactive
Start: 2013-01-04
End: 2015-09-17

CAVD 406
CAVD 406 is a preclinical rabbit study for epitope mapping of serum antibody responses in order to understand how different N-glycans on immunogen play a role in the antibody repertoire in immunized animals.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Shan Lu
Lu: Creating a Better Envelope

Protein & peptide vaccines

Product info coming soon!

Inactive
Start: 2013-01-14
End: 2015-02-26

CAVD 408
CAVD 408 (AUP 518) is a non-human primate study comparing NYVAC/protein-adjuvant prime/boost regimens.

BAMA, ICS, NAb

Pre-Clinical NHP
Rhesus macaque

Giuseppe Pantaleo
Pantaleo: RepliVax Vaccine Platform

Combo: Protein & vector vaccines

GLA
Poly ICLC
Placebo Unspecified
NYVAC-KC-gp140(ZM96)
gp140 Lox-1

Inactive
Start: 2013-01-24
End: 2016-10-12

CAVD 409
CAVD 409 is an immunogenicity study to isolate and characterize monoclonal antibodies from RV144, RV305, and RV306 human clinical trial subjects.

NAb MAb

Antibody Screening
Non-Organism Study

Barton Haynes
Haynes: Role of IgA in HIV-1 Protection

Prophylactic neutralizing Ab

ALVAC (vCP1521)
AIDSVAX B/E
Saline (non-specific)
Placebo ALVAC
Placebo AIDSVAX B/E

Inactive
Start: 2013-01-29
End: 2013-08-16

CAVD 410
CAVD 410 is an immunogenicity study of monoclonal antibodies using plant-based biotechnology to produce monoclonal antibody/env complexes using plant biotechnology that are effective immunogens.

NAb MAb

Antibody Production
Plant

Robin Shattock
Shattock: Novel Antigens for Mucosal Protection

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2013-02-01
End: 2013-07-25

CAVD 411
CAVD 411 is a preclinical rabbit study to evaluate and compare the anti-viral antibody response of 3 combinations of Clade C HIV envelope trimeric gp140 proteins in a protein/adjuvant vaccine regimen.

NAb

Pre-Clinical Non-NHP
Rabbit

Julie McElrath
McElrath: Innate to Adaptive Immunity

Protein & peptide vaccines

PEI
Env gp140 CN54 trimeric
Env gp140 590c
Env gp140 823c
Env gp140 756c
Env gp140 CN54/590c/756c/823c

Inactive
Start: 2013-02-21
End: 2015-05-12

CAVD 412
CAVD 412 (Study 31) is a non-human primate study to evaluate different protein prime/boost regimens to induce HIV-1 env-specific CD4+ T-cell responses using recombinant vaccine vectors that express HIV-1 Env (1086C).

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Richard Koup
Koup: T Cell VIMC

Combo: DNA, protein & vector vaccines

MF59
1086 Env protein
rVSV-1086C Env
Plasmid DNA-1086C Env
rMVA-1086C Env

Inactive
Start: 2013-02-26
End: 2014-08-05

CAVD 413
CAVD 413 is an immunogenicity study to evaluate the neutralization activity of monoclonal antibodies isolated from the plasma of Clade B HIV-infected individuals in US and German cohorts.

No data is available for this study.

Antibody Screening
Non-Organism Study

Bruce Walker
Walker: bNabs after Infection and Immunization

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2013-03-11
End: 2013-10-16

CAVD 414
CAVD 414 is a preclinical rabbit study evaluating the neutralization activities induced by prime-boost immunization regimens using different forms of Env proteins.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Shan Lu
Lu: Creating a Better Envelope

Combo: DNA & protein vaccines

Product info coming soon!

Inactive
Start: 2013-06-09
End: 2015-02-26

CAVD 415
CAVD 415 is a preclinical rabbit study comparing increasing doses of an inactivated Vesicular Stomatitis Virus (VSV) vector and adjuvant.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Christopher Parks
Parks: iVSV –HIVEnv

Vector vaccines (viral or bacterial)

Iscomatrix
JRFL Foldon
iVSVdeltaG HIV EnvG-JRFL
iVSVdeltaG HIV-EnvG-BG505
Adju-Phos

Inactive
Start: 2013-06-17
End: 2014-03-07

CAVD 417
CAVD 417 (VRC 422) is a non-human primate study of protein and adjuvant regimens. This was a follow up study to confirm the results of CAVD 266

NAb

Pre-Clinical NHP
Rhesus macaque

Julie McElrath
McElrath: Innate to Adaptive Immunity

Protein & peptide vaccines

Alum
Saline (non-specific)
MF59
Poly ICLC
TLR7
Env gp140 TV1

Inactive
Start: 2013-07-02
End: 2016-03-30

CAVD 418
CAVD 418 is preclinical rabbit study to determine the epitopes of immune sera elicited by either DNA prime-protein boost or co-delivery of DNA and protein vaccines.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Shan Lu
Lu: Creating a Better Envelope

Combo: DNA & protein vaccines

Product info coming soon!

Inactive
Start: 2013-07-06
End: 2015-02-26

CAVD 419
CAVD 419 is a non-human primate challenge study comparing immune responses in DNA/ALVAC-protein and Ad26/ALVAC-protein prime/boost regimens.

ICS, ELISpot

Pre-Clinical NHP
Rhesus macaque

Genoveffa Franchini
Third party request

Combo: DNA, protein & vector vaccines

Alum
MF59
ALVAC-SIV
Ad26-SIV
DNA-SIV
SIVmac251
A244 gD-gp120

Inactive
Start: 2013-07-17
End: 2013-11-08

CAVD 421
CAVD 421 (NHP Study #38.2) is a non-human primate study of a passive immunization regimen with the non-neutralizing gp41-binding antibody.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Barton Haynes
Haynes: Role of IgA in HIV-1 Protection

Prophylactic neutralizing Ab

7B2-AAA mAb

Inactive
Start: 2013-08-08
End: 2015-06-29

CAVD 422
CAVD 422 is a non-human primate challenge study comparing passive immunization regimens using broadly neutralizing monoclonal antibodies.

NAb

Pre-Clinical NHP
Rhesus macaque

Robert Gallo
Gallo: Systemic, Mucosal & Passive Immunity

Prophylactic neutralizing Ab

SHIV162p3
N60-B1.1
N12-i2
N12-i2 LALA
N60-B1.1 LALA
IgG B12
None

Inactive
Start: 2013-08-21
End: 2014-01-09

CAVD 423
CAVD 423 is a non-human primate challenge study comparing Vesicular Stomatitis Virus (VSV) vector, adenovirus vector, and protein prime/boost regimens.

NAb

Pre-Clinical NHP
Rhesus macaque

Christopher Parks
Parks: CDV and VSV Viral Vectors

Combo: Protein & vector vaccines

Iscomatrix
Placebo Ad5
Ad5-SIV-Env
Ad5-SIV-Gag
SIVmac239
JRFL Foldon
VSVdeltaG-HIVENV(JTFL)
VSVdeltaG-SIVEnvGag
VSVdeltaG-SIVEnvGag with VSVG
Placebo VSV
SHIV-SF162P3

Inactive
Start: 2013-08-22
End: 2016-03-10

CAVD 425
CAVD 425 is a monoclonal antibody characterization study to evaluate the neutralization activity of monomeric and dimeric recombinant IgAs (and IgG controls).

NAb MAb

Antibody Screening
Non-Organism Study

Barton Haynes
Haynes: Role of IgA in HIV-1 Protection

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2013-09-17
End: 2016-01-15

CAVD 426
CAVD 426 is an antibody screening study to isolate and characterize monoclonal antibodies from RV144, RV305, and RV306 human clinical trial subjects.

NAb MAb

Antibody Screening
Non-Organism Study

Barton Haynes
Haynes: B-Cell Lineage Envelope Design

Prophylactic neutralizing Ab

ALVAC (vCP1521)
AIDSVAX B/E
Saline (non-specific)
Placebo ALVAC
Placebo AIDSVAX B/E

Inactive
Start: 2013-09-17
End: 2015-06-29

CAVD 427
CAVD 427 is a preclinical rabbit study evaluating the neutralization activities and epitope mapping of Man9 Env (from Pichia pastoris) and CHO-Env immunized sera.

No data is available for this study.

Pre-Clinical Non-NHP
Rabbit

Shan Lu
Lu: Creating a Better Envelope

Protein & peptide vaccines

Product info coming soon!

Inactive
Start: 2013-09-18
End: 2015-03-10

CAVD 429
CAVD 429 is a monoclonal antibody screening study evaluating broadly neutralizing antibodies from HIV infected, long-term non-progressors.

NAb MAb

Antibody Screening
Non-Organism Study

Bruce Walker
Walker: bNabs after Infection and Immunization

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2013-10-02
End: 2015-01-13

CAVD 430
CAVD 430 is an immunogenicity study to evaluate the neutralization of specimens from NHP Study 64 that compared ALVAC/protein prime/boost regimens.

NAb

Pre-Clinical NHP
Rhesus macaque

Barton Haynes
Haynes: B-Cell Lineage Envelope Design

Combo: Protein & vector vaccines

ALVAC (vCP1521)
GLA-SE (IDRI-EM005)
gp120 pentavalent
gp120 bivalent

Inactive
Start: 2013-10-07
End: 2015-06-29

CAVD 431
CAVD 431 is a non-human primate challenge study comparing canine distemper and adenovirus viral vector prime/boost regimens.

NAb

Pre-Clinical NHP
Rhesus macaque

Christopher Parks
Parks: CDV and VSV Viral Vectors

Vector vaccines (viral or bacterial)

Placebo Ad5
Ad5-SIV-Env
Ad5-SIV-Gag
Placebo CDV
SIVmac239
CDV-SIVmac239-Env (mem)
CDV-SIVmac239-Env (soluble)
CDV-SIVmac239-Gag (myr+)
CDV-SIVmac239-Gag (myr-)

Inactive
Start: 2013-10-16
End: 2014-10-06

CAVD 432
CAVD 432 is a non-human primate study of protein and adjuvant regimens.

BAMA, NAb

Pre-Clinical NHP
Rhesus macaque

Bali Pulendran
Pulendran: Protective humoral responses against HIV

Protein & peptide vaccines

Alum
gp140 (1086C)
PLGA (MPL)
PLGA (R848)
PLGA (3M-052)
PGLA (GLA)

Inactive
Start: 2013-10-21
End: 2018-10-18

CAVD 433
CAVD 433 is a monoclonal antibody screening study evaluating neutralizing antibodies.

No data is available for this study.

Antibody Screening
Non-Organism Study

Bruce Walker
Walker: bNabs after Infection and Immunization

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2013-10-24
End: 2014-10-06

CAVD 434
CAVD 434 (AUP 567) is a non-human primate study comparing NYVAC/protein-adjuvant prime/boost regimens.

BAMA, ICS, NAb

Pre-Clinical NHP
Rhesus macaque

Giuseppe Pantaleo
Pantaleo: RepliVax Vaccine Platform

Combo: Protein & vector vaccines

Poly ICLC
NYVAC-KC-gp140(ZM96)
NYVAC-KC-Gag(ZM96)Pol-Nef(CN54)
αCD40-gp140Z
αLOX-1-gp140Z

Inactive
Start: 2013-11-04
End: 2016-03-10

CAVD 435
CAVD 435 is an immunogenicity study of broadly neutralizing antibodies to investigate the development of four germline versions of broadly neutralizing antibodies (bNAbs) that were previously identified in HIV-infected patients.

No data is available for this study.

Antibody Screening
Non-Organism Study

Michel Nussenzweig
Nussenzweig: Discovery & Characterization of bNAbs

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2013-12-20
End: 2015-08-28

CAVD 436
CAVD 436 is an immunogenicity study evaluating the immunogenicity of novel glycan modified Env protein by epitope mapping rabbit sera induced with glycan modified Envs produced in Pichia pastoris .

NAb

Pre-Clinical Non-NHP
Rabbit

Shan Lu
Lu: Creating a Better Envelope

Protein & peptide vaccines

Alum
Iscomatrix
GF15.0 Env
GF16.0 Env
GF12.1 Env
CHO Env
DNA Env

Inactive
Start: 2013-12-31
End: 2015-03-03

CAVD 438
CAVD 438 is an immunogenicity study to evaluate the potency and breadth of broadly neutralizing antibodies isolated from HIV-1 infected donors.

No data is available for this study.

Antibody Screening
Non-Organism Study

George Lewis
Lewis: Ab Specificity & Fc-Mediated Protection

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2014-01-09
End: 2015-02-02

CAVD 441
CAVD 441 is an immunogenicity study evaluating neutralizing antibody breadth in plasma from HIV-infected participants.

No data is available for this study.

Antibody Screening
Human

Bruce Walker
Walker: bNabs after Infection and Immunization

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2014-02-14
End: 2016-03-14

CAVD 442
CAVD 442 is a preclinical guinea pig study comparing 3 epitope-rich structures (ERS) of the HIV-1 envelope (gp41fi, bV3, and V1V2) to the entire envelope.

No data is available for this study.

Pre-Clinical Non-NHP
Guinea Pig

Jonathan Heeney
Third party request

Protein & peptide vaccines

Product info coming soon!

Inactive
Start: 2014-02-19
End: 2014-10-06

CAVD 443
CAVD 443 is a preclinical rabbit study comparing Vesicular Stomatitis Virus (VSV) vector, DNA, and protein regimens with and without adjuvant.

NAb

Pre-Clinical Non-NHP
Rabbit

Christopher Parks
Parks: iVSV –HIVEnv

Combo: DNA, protein & vector vaccines

Iscomatrix
iVSVdeltaG HIV EnvG-JRFL
iVSVdeltaG HIV-EnvG-BG505
Adju-Phos
BG505 pDNA
BG505 gp120

Inactive
Start: 2014-03-06
End: 2015-02-02

CAVD 446
CAVD 446 (Protocol # MCA-835) is a Phase 1, open label, dose-escalation study of the safety, pharmacokinetics andantiretroviral activity of 3BNC117 monoclonal antibody in HIV-infected and HIV-uninfected volunteers.

PK MAb, Demographics (Supplemental)

Phase I
Human

Michel Nussenzweig
Nussenzweig: Discovery & Characterization of bNAbs

Prophylactic neutralizing Ab

3BNC117

Inactive
Start: 2014-03-11
End: 2019-07-24

CAVD 447
CAVD 447 (TP008) is an immunogenicity study to determine the in vitro efficacy of broadly neutralizing HIV antibodies produced in Nicotiana benthamiana plants.

NAb MAb

Antibody Production
Plant

Mike McLean
Third party request

Prophylactic neutralizing Ab

No Products used in study

Inactive
Start: 2014-03-11
End: 2014-10-03

CAVD 448
CAVD 448 is a preclinical mouse study comparing immunogenicity following wild type versus cytoplasmic tail-modified 89.6 N7 Env prime/boost regimens.

No data is available for this study.

Pre-Clinical Non-NHP
Mouse

Shiu-Lok Hu
Hu: Unmasking Conserved Epitopes

Vector vaccines (viral or bacterial)

Product info coming soon!

Inactive
Start: 2014-04-07
End: 2014-10-06

CAVD 449
CAVD 449 is a preclinical rabbit study to evaluate the antibody responses following vaccinia vector and heterologous N7 Env prime/boost regimens.

NAb

Pre-Clinical Non-NHP
Rabbit

Shiu-Lok Hu
Hu: Unmasking Conserved Epitopes

Combo: Protein & vector vaccines

Alum
Env gp120 (89.6 N7)
v-NY-Env gp160 (89.6 N7)
PV0.4 N7 gp120
v-NY Env gp160 (N7 mix)
v-WR Env gp160 (89.6 N7)
Env gp120 (JR-FL WT)
Env gp120 (1084i N7)

Inactive
Start: 2014-04-08
End: 2016-10-12

CAVD 451
CAVD 451 (MX1) is a non-human primate study to evaluate the antibody responses following vaccinia vector and heterologous N7 Env prime/boost regimens.

BAMA, ICS, NAb

Pre-Clinical NHP
Rhesus macaque

Shiu-Lok Hu
Hu: Unmasking Conserved Epitopes

Combo: DNA, protein & vector vaccines

Alum
DNA-SIV-Gag-Pol
v-NY-SIV gag/pol
Env gp120 (89.6 N7)
v-NY-Env gp160 (89.6 N7)
JRFL gp120
Placebo vaccinia
PV0.4 N7 gp120
v-NY Env gp160 (N7 mix)
Env gp120 (N7 mix)
1084i (C) N7 gp120
v-WR Env gp160 (89.6 N7)

Inactive
Start: 2014-04-08
End: 2017-07-27

CAVD 452
CAVD 452 is an immunogenicity study to evaluate ADCC activity in specimens from RV305, the follow up and boosting study to the RV144 clinical trial.

No data is available for this study.

Phase III
Human

Barton Haynes
Haynes: B-Cell Lineage Envelope Design

Combo: Protein & vector vaccines

ALVAC (vCP1521)
AIDSVAX B/E
Saline (non-specific)
Placebo ALVAC
Placebo AIDSVAX B/E

Inactive
Start: 2014-04-08
End: 2016-10-20

CAVD 453
CAVD 453 is a non-human primate challenge study comparing neutralizing antibody responses in simian adenovirus/protein prime/boost regimens.

NAb

Pre-Clinical NHP
Rhesus macaque

Dan Barouch
Barouch: Novel Vector/Protein Vaccines

Combo: Protein & vector vaccines

acute Clade C gp140 protein
AS01B
ChAd24
RhAd52
RhAd53
PBS

Inactive
Start: 2014-05-13
End: 2016-01-15

CAVD 454
CAVD 454 is an immunogenicity study to characterize the neutralization of monoclonal antibodies from RV144 human clinical trial vaccine recipients.

No data is available for this study.

Antibody Screening
Non-Organism Study

Barton Haynes
Haynes: B-Cell Lineage Envelope Design

Prophylactic neutralizing Ab

ALVAC (vCP1521)
AIDSVAX B/E
Saline (non-specific)
Placebo ALVAC
Placebo AIDSVAX B/E

Inactive
Start: 2014-05-27
End: 2016-11-01

CAVD 456
CAVD 456 (RM1401) is a non-human primate challenge study comparing Canine Distemper Virus (CDV) and Vesicular Stomatitis Virus (VSV) vectors.

BAMA, NAb

Pre-Clinical NHP
Rhesus macaque

Christopher Parks
Parks: CDV and VSV Viral Vectors

Vector vaccines (viral or bacterial)

SHIV162p3
rVSVdeltaG-HIVEnvG
rVSVdeltaG-HIVEnvG-G6
rCDV-HIVEnv

Inactive
Start: 2014-06-16
End: 2019-01-28

CAVD 457
CAVD 457 is a preclinical guinea pig study of a biochemically stable HIV-1 Clade C (459C) gp140 Env trimer with epitope-optimized V2 and V3 loops.

No data is available for this study.

Pre-Clinical Non-NHP
Guinea Pig

Dan Barouch
Barouch: Novel Vector/Protein Vaccines

Protein & peptide vaccines

CpG DNA
Env gp140 459C WT
Env gp140 459C V2-Opt
Env gp140 459C V2-Alt
Env gp140 459C V2-Alt/V2-Opt
Env gp140 459C WT/V2-Alt/V2-Opt
Env gp140 459C V2-Opt Prime
Env gp140 459C V3-Opt
Env gp140 459C V3-Alt
Env gp140 459C V3-Alt/V3-Opt
Env gp140 459C V3-Opt Prime
Env gp140 459C WT/V3-Alt/V3-Opt
EMULSIGEN ®
Env gp140 459C WT/V2-Alt
Env gp140 459C WT/V3-Alt

Inactive
Start: 2014-06-25
End: 2017-05-04

CAVD 458
CAVD 458 is a preclinical mouse study to evaluate cytoplasmic tail modifications that increase Env surface expression in the context of a vaccinia virus/Env prime-Env protein boost regimen.

No data is available for this study.

Pre-Clinical Non-NHP
Mouse

Shiu-Lok Hu
Hu: Unmasking Conserved Epitopes

Combo: Protein & vector vaccines

Alum
v-NY-SIV gag/pol
Env gp120 (89.6 N7)
v-NY-Env gp160 (89.6 N7)
v-NY-Env gp160 (89.6 N7) HM
v-NY-Env gp160 (89.6 N7) FM

Inactive
Start: 2014-07-07
End: 2016-02-16

CAVD 460
CAVD 460 is a non-human primate challenge study to compare immunogenicity and protection following administration with CMV/SIV vector immunogens, delta-pp71 RhCMV/SIVmac239 versus delta-pp71 RhCMV/SIVsmE660.

No data is available for this study.

Pre-Clinical NHP
Rhesus macaque

Louis Picker
Picker: An Attenuated CMV Vector

Vector vaccines (viral or bacterial)

SIVmac239
delta-pp71 RhCMV/SIVmac239
delta-pp71 RhCMV/SIVsmE660

Inactive
Start: 2014-09-09
End: 2017-02-08

CAVD 461
CAVD 461 is an immunogenicity study of broadly neutralizing antibodies.